Oncimmune Regulatory News (ONC)

1 July 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Total Voting Rights

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.

Pursuant to the Company's existing block admission, and following the exercise of options over 6,482 ordinary shares in aggregate during May and June 2021 by current and former employees, as at 30 June 2021, the Company's issued share capital was 69,121,949 ordinary shares of £0.01 each with voting rights. The Company does not hold any shares in treasury.

The above figure of 69,121,949 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, James Hornigold

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Claes Spång

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000